Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences. Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-17-486.html

The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness.

SUMMARY OF WORK: The non-federal entity will perform the required program support to: (1) provide technical assistance and support related to the successful completion of National Environmental Policy Act (NEPA) and Environmental Condition of Property (ECP) documentation for integrated and interdisciplinary environmental planning; (2) support the installation in the proper disclosure technical environmental information to the public; and (3) enhance government environmental planning and decision making during the NEPA process by supporting the collection and analysis of technical environmental information related to scoping, alternative analysis, and direct, indirect, and cumulative environmental impacts. BACKGROUND: Fort Leonard Wood currently consists of 61,410 acres and is designated as an active Installation Management Command (IMCOM) installation. Fort Leonard Wood is located just south of Waynesville and St. Robert, in Pulaski County, Missouri located in the northern Ozark Highland region of south-central Missouri. The installation encompasses 61,000 acres of primarily upland oak-hickory forest, 19/25 miles of permanent/intermittent streams, and 240 acres of impoundments that support an abundance of terrestrial and aquatic flora and fauna, including sensitive species. ELIGIBILITY REQUIREMENTS: All responsible, non-federal entities submitting funding requests that meet the requirements in the scope of work will be considered for this funding opportunity. STATUTORY AUTHORITY: Title 16 U.S.C. Section 670c-1 provides, in part, that "[t]he Secretary of a military department may enter into cooperative agreements…with nongovernmental organizations" for the purposes of "[t]he maintenance and improvement of natural resources on, or to benefit natural and historic research on, military installations and State-owned National Guard installations."

This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets.

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research on Zika virus (ZIKV) and its complications. This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects. The last date for submitting an application to PAR-16-106 is January 13, 2017.

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research

The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.

This funding opportunity announcement (FOA) seeks to stimulate research that tests optimal end-of-life and palliative care (EOLPC) interventions/models of care that are based on individual- and family-centered outcomes. The testing of EOLPC interventions and models of care are urgently needed that address racial, ethnic and/or cultural diversity in children and adults for those with serious, advanced illness. Trials are needed to test efficacy and effectiveness of these interventions and/or models of care.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that examines the relationship between asthma, obesity and self-management. It seeks to build the science of obesity, asthma, and self-management awareness.

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.

As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.

The purpose of this Funding Opportunity Announcement (FOA) is to support research that will identify changes in immune mechanisms and markers because of Mycobacterium tuberculosis (M.tb) exposure, infection or disease in pediatric populations exposed to or infected with HIV-1.

The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Applications can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children.

NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing.

The purpose of the Funding Opportunity Announcement (FOA) is to encourage research into the role of pluripotent progenitor/stem cells in the pathogenesis and treatment of selected gynecologic disorders, specifically uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to evaluate the cumulative and progressive effects on brain structure and cognitive/behavioral function of combined HIV infection and alcohol abuse. This project has recruited and longitudinally tracked a large cohort of individuals with HIV infection, or alcohol abuse, or the comorbid condition. As members of this cohort are growing older and living well longer due to antiretroviral medications, this project is well suited to address several questions of current interest in the HIV-AIDS research community. These questions include the effects of coinfection with the Hepatitis C virus, the involvement of peripheral neuropathy as a factor in frailty, potential neurotoxic effects of antiretroviral medications, and interactive effects with advancing age on sensory and motor functioning.

Grants are targeted primarily to new or junior investigators within seven years of attaining a terminal degree (e.g., PhD, EdD), and are expected to provide seed-money support after which further funding will be sought from other sources.

Through the program, NKF will award grants of up to $35,000 in support of research projects in the field of nephrology and related disciplines conducted by individuals who have completed fellowship training and who hold a junior faculty position at a university-affiliated medical center in the United States.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

The program provides support to nonprofits interested in making long-term improvements in their management, governance, and/or organizational capacity. Grants may be used for capacity-building activities that include but are not limited to strategic planning; financial management, including cash flow, budget development, and financial controls; program evaluation planning; communications and marketing, including website development, public relations, and the use of social media; resource development and fundraising; human resources, including professional development, succession planning, staffing structure, assessment, and retention; information systems management, including technology enhancements; board development, including assessment, recruitment, training, and structuring; and restructuring and relationship building with other nonprofit organizations aimed at strengthening service delivery, reducing costs, and sharing resources.